HIMS
The sugar rush might be fading
Bank of America is out with a fresh reality check on Hims & Hers: the company may have a very steep climb to hit its 2026 guidance. The big worry is Wegovy churn — aka the possibility that customers who came in for the GLP-1 boom don’t stick around once the shiny weight-loss excitement cools off.
That matters because Hims has been sold, at least in part, like a consumer-health growth machine with a fintech-ish subscription twist. But if a meaningful chunk of demand is tied to a single blockbuster therapy, then the whole story starts to look less like a smooth escalator and more like one of those mall escalators that randomly stops when you need it most.
What BofA is really flagging
The note suggests Hims may need to overcome a few nasty little math problems at once:
- it has to keep adding new customers fast enough to offset churn
- it has to prove the Wegovy-driven demand isn’t just a passing wave
- it has to show that 2026 guidance isn’t built on a best-case script with extra optimism baked in
That’s the kind of setup investors should watch closely. When a stock gets priced for rapid growth, even a modest wobble in customer retention can hit sentiment like a pop quiz you forgot was happening.
Why you should care
This is not just about one analyst taking a skeptical lap around the track. Hims has been leaning hard into the idea that it can scale fast, own the digital-health lane, and keep the momentum going. If BofA is right, the market may need to recalibrate how much of that upside is durable versus temporary.
Big picture: the Hims story still has plenty of fans, but this report says the company may need to do more than ride the Wegovy wave. It has to prove it can keep people on board after the surfboard stops looking so fun.